Lates News

Lilly has signed a licensing and development agreement with Camurus. Both parties will jointly develop long-acting insulin drugs for the treatment of obesity, diabetes, and other metabolic diseases based on Camurus' FluidCrystal technology. The agreement allows Lilly to develop up to four proprietary drug compounds, including GIP/GLP-1 receptor agonists, GIP/glucagon-like peptide/GLP-1 receptor agonists, and options including glucagon receptor agonists. Meanwhile, under the agreement, Camurus is eligible to receive potential development and sales milestone payments of up to $870 million, as well as royalties in the mid-single digits.